Compare Davita Inc (DVA) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Taskus Inc — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while Taskus Inc trades at $5.61 (market cap $530.70M). The key difference: Davita Inc is far larger — about 28.1× Taskus Inc's market cap, and Davita Inc is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| DVA | TASK | |
|---|---|---|
Market Cap | $14.92B | $530.70M |
Sector | Health | Technology |
52-Week High | $235.71 | $18.21 |
52-Week Low | $103.87 | $4.57 |
Enterprise Value | $27.47B | $926.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
TaskUs (TASK) trades at $5.62, up 3.88% with strong valuation metrics including P/E of 4.97 and P/S of 0.43. The company reported Q1 2026 earnings miss but maintains solid fundamentals with 8.7% net margin and 26.52% ROE. Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages. Recent CFO appointment and robotaxi survey highlight growth initiatives.
The stock appears undervalued with 69% upside to consensus target of $9.50. Strong cash flow generation and improving debt-to-asset ratio (22.96% in 2025) support bullish case. Risks include competitive pressures and earnings volatility. Analyst consensus leans bullish with 55% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
